Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Taletrectinib
DRUG: Placebo

Sponsor

Nuvation Bio Inc.